Key summary
- No date has been fixed for Claire Mazumdar to take charge, but she may do so 'at the right time'.
- Mazumdar-Shaw is preparing the four-decade-old group for its next phase of growth, driven by advanced biotechnology innovation and artificial intelligence.
- Biocon aims to strengthen its biosimilar portfolio, with 12 products already in the market and around 20 in the pipeline.
Biocon founder and chairperson Kiran Mazumdar-Shaw has indicated that she has chosen her niece Claire Mazumdar as successor as she prepares the biotechnology major for a future leadership shift.
Mazumdar-Shaw, 73, who has built Biocon into India’s largest biotechnology company, has no children, and her late husband, John Shaw, was vice chairman of the group.
Though no date has been fixed for Claire Mazumdar to take charge, she is expected to join in the foreseeable future, Fortune India magazine reports.
"Claire will transition into my role at the right time so not planning to hang up my boots just yet!," Mazumdar-Shaw said on X (formerly Twitter).
The 37-year-old biotech specialist currently serves as founder-CEO of Bicara Therapeutics, a NASDAQ-listed company incubated by Biocon.
She holds a degree in Biological Engineering from Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business, and a PhD in Cancer Biology from Stanford School of Medicine.
Before taking over as the CEO of Bicara in 2018, Claire Mazumdar had worked with venture capital firm Third Rock Ventures and medicine development company Rheos Medicines.
Mazumdar-Shaw is preparing the four-decade-old group for its next phase of growth, driven by advanced biotechnology innovation and artificial intelligence.
In recent months, Biocon had merged its generics and biologics businesses, simplified its corporate structure, and reduced debt.
The company aims to strengthen its biosimilar portfolio, with 12 products already in the market and around 20 in the pipeline.
Biocon veteran Shreehas Tambe took over as CEO and managing director of the merged entity from April 1.
